CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice4-Year Results From a Large 2-Institutional Cohort Study
Peter Wenaweser, MD*,
Joost Daemen, MD ,
Marcel Zwahlen, PhD ,
Ron van Domburg, PhD,
Peter Jüni, MD,
Sophia Vaina, MD, PhD,
Gerrit Hellige, MD*,
Keiichi Tsuchida, MD,
Cyrill Morger, MD*,
Eric Boersma, PhD,
Neville Kukreja, MBBS, MRCP,
Bernhard Meier, MD*,
Patrick W. Serruys, MD, PhD and
Stephan Windecker, MD*,*
* Department of Cardiology, University of Bern, Bern, Switzerland
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands
Manuscript received March 18, 2008;
revised manuscript received June 30, 2008,
accepted July 1, 2008.
* Reprint requests and correspondence: Dr. Stephan Windecker, Department of Cardiology, University Hospital Bern, 3010 Bern, Switzerland (Email: stephan.windecker{at}insel.ch).
Objectives: We sought to determine the risk of late stent thrombosis (ST) during long-term follow-up beyond 3 years, searched for predictors, and assessed the impact of ST on overall mortality.
Background: Late ST was reported to occur at an annual rate of 0.6% up to 3 years after drug-eluting stent (DES) implantation.
Methods: A total of 8,146 patients underwent percutaneous coronary intervention with a sirolimus-eluting stent (SES) (n = 3,823) or paclitaxel-eluting stent (PES) (n = 4,323) and were followed up to 4 years after stent implantation. Dual antiplatelet treatment was prescribed for 6 to 12 months.
Results: Definite ST occurred in 192 of 8,146 patients with an incidence density of 1.0/100 patient-years and a cumulative incidence of 3.3% at 4 years. The hazard of ST continued at a steady rate of 0.53% (95% confidence interval [CI]: 0.44 to 0.64) between 30 days and 4 years. Diabetes was an independent predictor of early ST (hazard ratio [HR]: 1.96; 95% CI: 1.18 to 3.28), and acute coronary syndrome (HR: 2.21; 95% CI: 1.39 to 3.51), younger age (HR: 0.97; 95% CI: 0.95 to 0.99), and use of PES (HR: 1.67; 95% CI: 1.08 to 2.56) were independent predictors of late ST. Rates of death and myocardial infarction at 4 years were 10.6% and 4.6%, respectively.
Conclusions: Late ST occurs steadily at an annual rate of 0.4% to 0.6% for up to 4 years. Diabetes is an independent predictor of early ST, whereas acute coronary syndrome, younger age, and PES implantation are associated with late ST.
Key Words: drug-eluting stent • mortality • stent thrombosis
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | ARC = Academic Research Consortium | | ASA = acetylsalicylic acid | | BMS = bare-metal stent(s) | | CI = confidence interval | | DES = drug-eluting stent(s) | | MACE = major adverse cardiac event | | MI = myocardial infarction | | PES = paclitaxel-eluting stent(s) | | SES = sirolimus-eluting stent(s) | | ST = stent thrombosis | | TIMI = Thrombolysis In Myocardial Infarction |
|
This article has been cited by other articles:
|
|
|
|
 
T. Kimura, T. Morimoto, Y. Nakagawa, K. Kawai, S. Miyazaki, T. Muramatsu, N. Shiode, M. Namura, T. Sone, S. Oshima, et al.
Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation: Five-Year Outcome of the j-Cypher Registry
Circulation,
January 31, 2012;
125(4):
584 - 591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Faxon
Very Late Stent Thrombosis and Late Target Lesion Revascularization: No End in Sight
Circulation,
January 31, 2012;
125(4):
562 - 564.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Sarno, B. Lagerqvist, O. Frobert, J. Nilsson, G. Olivecrona, E. Omerovic, N. Saleh, D. Venetzanos, and S. James
Lower risk of stent thrombosis and restenosis with unrestricted use of 'new-generation' drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 9, 2012;
(2012)
ehr479v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. F. Granada, M. J. Price, P. A. French, S. R. Steinhubl, D. E. Cutlip, R. C. Becker, S. S. Smyth, and H. L. Dauerman
Platelet-Mediated Thrombosis and Drug-Eluting Stents
Circ Cardiovasc Interv,
December 1, 2011;
4(6):
629 - 637.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kirtane and G. W. Stone
How to Minimize Stent Thrombosis
Circulation,
September 13, 2011;
124(11):
1283 - 1287.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wohrle, R. Birkemeyer, S. Markovic, T.-V. Nguyen, A. Sinha, T. Miljak, J. Spiess, W. Rottbauer, and H. Rittger
Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease
Heart,
August 15, 2011;
97(16):
1338 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Klauss, P. W. Serruys, T. Pilgrim, P. Buszman, A. Linke, T. Ischinger, F. Eberli, R. Corti, W. Wijns, M.-C. Morice, et al.
2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice
J. Am. Coll. Cardiol. Intv.,
August 1, 2011;
4(8):
887 - 895.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. Smits, E. Kedhi, K.-J. Royaards, K. S. Joesoef, J. Wassing, T. A. M. Rademaker-Havinga, and E. McFadden
2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial)
J. Am. Coll. Cardiol.,
June 28, 2011;
58(1):
11 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, L. Wohlwend, M. Wigger, M. Togni, S. Wandel, P. Wenaweser, S. Cook, A. Moschovitis, R. Vogel, B. Kalesan, et al.
Five-Year Clinical and Angiographic Outcomes of a Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents: Results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE Trial
Circulation,
June 21, 2011;
123(24):
2819 - 2828.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Pilgrim, L. Raber, A. Limacher, L. Loffel, P. Wenaweser, S. Cook, J.-C. Stauffer, M. Togni, R. Vogel, A. Garachemani, et al.
Comparison of Titanium-Nitride-Oxide-Coated Stents With Zotarolimus-Eluting Stents for Coronary Revascularization: A Randomized Controlled Trial
J. Am. Coll. Cardiol. Intv.,
June 1, 2011;
4(6):
672 - 682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Stefanini, P. W. Serruys, S. Silber, A. A. Khattab, R. J. van Geuns, G. Richardt, P. E. Buszman, H. Kelbaek, A. J. van Boven, S. H. Hofma, et al.
The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents: A Substudy of the RESOLUTE All Comers Trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention)
J. Am. Coll. Cardiol.,
May 31, 2011;
57(22):
2221 - 2232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Raber, P. Juni, E. Nuesch, B. Kalesan, P. Wenaweser, A. Moschovitis, A. A. Khattab, M. Bahlo, M. Togni, S. Cook, et al.
Long-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
J. Am. Coll. Cardiol.,
May 24, 2011;
57(21):
2143 - 2151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ikesue, Y. Matsui, D. Ohta, K. Danzaki, K. Ito, M. Kanayama, D. Kurotaki, J. Morimoto, T. Kojima, H. Tsutsui, et al.
Syndecan-4 Deficiency Limits Neointimal Formation After Vascular Injury by Regulating Vascular Smooth Muscle Cell Proliferation and Vascular Progenitor Cell Mobilization
Arterioscler Thromb Vasc Biol,
May 1, 2011;
31(5):
1066 - 1074.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Dangas, A. Caixeta, R. Mehran, H. Parise, A. J. Lansky, E. Cristea, B. R. Brodie, B. Witzenbichler, G. Guagliumi, J. Z. Peruga, et al.
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction
Circulation,
April 26, 2011;
123(16):
1745 - 1756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Urban, A. Abizaid, A. Banning, A. L. Bartorelli, A. C. Baux, V. Dzavik, S. Ellis, R. Gao, D. Holmes, M. H. Jeong, et al.
Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population: A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry
J. Am. Coll. Cardiol.,
March 29, 2011;
57(13):
1445 - 1454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Onuma and P. W. Serruys
Bioresorbable Scaffold: The Advent of a New Era in Percutaneous Coronary and Peripheral Revascularization?
Circulation,
February 22, 2011;
123(7):
779 - 797.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Nakamura, B. C. Brott, I. Brants, D. Panchal, J. Li, J. P. Chen, S. B. King III, N. Chronos, and D. Hou
Vasomotor Function After Paclitaxel-Coated Balloon Post-Dilation in Porcine Coronary Stent Model
J. Am. Coll. Cardiol. Intv.,
February 1, 2011;
4(2):
247 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Capodanno, C. Tamburino, G. M. Sangiorgi, E. Romagnoli, A. Colombo, F. Burzotta, G. L. Gasparini, L. Bolognese, L. Paloscia, P. Rubino, et al.
Impact of Drug-Eluting Stents and Diabetes Mellitus in Patients With Coronary Bifurcation Lesions: A Survey From the Italian Society of Invasive Cardiology
Circ Cardiovasc Interv,
February 1, 2011;
4(1):
72 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-W. Park, Y.-H. Kim, H.-G. Song, J.-M. Ahn, J. Oh, W.-J. Kim, J.-Y. Lee, S.-J. Kang, S.-W. Lee, C.-W. Lee, et al.
Long-Term Comparison of Drug-Eluting Stents and Coronary Artery Bypass Grafting for Multivessel Coronary Revascularization: 5-Year Outcomes From the Asan Medical Center-Multivessel Revascularization Registry
J. Am. Coll. Cardiol.,
January 11, 2011;
57(2):
128 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, D. J. Kereiakes, S. Garg, P. W. Serruys, G. J. Dehmer, S. G. Ellis, D. O. Williams, T. Kimura, and D. J. Moliterno
Stent Thrombosis
J. Am. Coll. Cardiol.,
October 19, 2010;
56(17):
1357 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Simsek, M. Magro, E. Boersma, Y. Onuma, S. T. Nauta, M. P. Gaspersz, W. J. van der Giessen, R. T. van Domburg, P. W. Serruys, and on behalf of the Interventional Cardiologists of t
The Unrestricted Use of Sirolimus- and Paclitaxel-Eluting Stents Results in Better Clinical Outcomes During 6-Year Follow-Up Than Bare-Metal Stents: An Analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) Registries
J. Am. Coll. Cardiol. Intv.,
October 1, 2010;
3(10):
1051 - 1058.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Takano, M. Yamamoto, M. Mizuno, D. Murakami, T. Inami, N. Kimata, K. Murai, N. Kobayashi, K. Okamatsu, T. Ohba, et al.
Late Vascular Responses From 2 to 4 Years After Implantation of Sirolimus-Eluting Stents: Serial Observations by Intracoronary Optical Coherence Tomography
Circ Cardiovasc Interv,
October 1, 2010;
3(5):
476 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Collins, R. Torguson, M. A. Gaglia Jr, G. Lemesle, A. I. Syed, I. Ben-Dor, Y. Li, G. Maluenda, K. Kaneshige, Z. Xue, et al.
Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?
Circulation,
September 14, 2010;
122(11):
1085 - 1090.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. de la Torre Hernandez, F. Alfonso, F. Gimeno, J. A. Diarte, R. Lopez-Palop, A. Perez de Prado, F. Rivero, J. Sanchis, M. Larman, J. F. Diaz, et al.
Thrombosis of Second-Generation Drug-Eluting Stents in Real Practice: Results From the Multicenter Spanish Registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2)
J. Am. Coll. Cardiol. Intv.,
September 1, 2010;
3(9):
911 - 919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Garg and P. W. Serruys
Coronary Stents: Current Status
J. Am. Coll. Cardiol.,
August 31, 2010;
56(10_Suppl_S):
S1 - S42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Templin, M. Meyer, M. F. Muller, V. Djonov, R. Hlushchuk, I. Dimova, S. Flueckiger, P. Kronen, M. Sidler, K. Klein, et al.
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy
Eur. Heart J.,
July 2, 2010;
31(14):
1792 - 1801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Serruys, Y. Onuma, S. Garg, P. Vranckx, B. De Bruyne, M.-C. Morice, A. Colombo, C. Macaya, G. Richardt, J. Fajadet, et al.
5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions
J. Am. Coll. Cardiol.,
March 16, 2010;
55(11):
1093 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shirai, T. Kimura, M. Nobuyoshi, T. Morimoto, K. Ando, Y. Soga, K. Yamaji, K. Kondo, K. Sakai, T. Arita, et al.
Impact of Multiple and Long Sirolimus-Eluting Stent Implantation on 3-Year Clinical Outcomes in the j-Cypher Registry
J. Am. Coll. Cardiol. Intv.,
February 1, 2010;
3(2):
180 - 188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Stenestrand, S. K. James, J. Lindback, O. Frobert, J. Carlsson, F. Schersten, T. Nilsson, B. Lagerqvist, and for the SCAAR/SWEDEHEART study group
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Eur. Heart J.,
January 2, 2010;
31(2):
177 - 186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Costa Jr, A. Sousa, A. C. Moreira, R. A. Costa, M. Cano, G. Maldonado, C. Campos, M. Carballo, R. Pavanello, and J. E. Sousa
Incidence and Predictors of Very Late (>=4 Years) Major Cardiac Adverse Events in the DESIRE (Drug-Eluting Stents in the Real World)-Late Registry
J. Am. Coll. Cardiol. Intv.,
January 1, 2010;
3(1):
12 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Vasa-Nicotera and T. Gershlick
Chapter 29 Stent thrombosis
Oxford Textbook of Interventional Cardiology,
January 1, 2010;
1(1):
med-9780199569083-chapter - med-9780199569083-chapter.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. B. Leon, D. E. Kandzari, E. L. Eisenstein, K. J. Anstrom, L. Mauri, D. E. Cutlip, E. Nikolsky, C. O'Shaughnessy, P. A. Overlie, A. J. Kirtane, et al.
Late Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions: 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1208 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Kim, I.-K. Jang, C. Fan, T. H. Kim, J.-S. Kim, S. M. Park, E.-Y. Choi, S. H. Lee, Y.-G. Ko, D. Choi, et al.
Evaluation in 3 Months Duration of Neointimal Coverage After Zotarolimus-Eluting Stent Implantation by Optical Coherence Tomography: The ENDEAVOR OCT Trial
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1240 - 1247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, et al.
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
Eur. Heart J.,
November 2, 2009;
30(22):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis
A Generation 2.5 Drug-Eluting Stent?
J. Am. Coll. Cardiol. Intv.,
October 1, 2009;
2(10):
986 - 988.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wijns and P. Kolh
Appropriate myocardial revascularization: a joint viewpoint from an interventional cardiologist and a cardiac surgeon
Eur. Heart J.,
September 2, 2009;
30(18):
2182 - 2185.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Roe, A. Y. Chen, C. P. Cannon, S. Rao, J. Rumsfeld, D. J. Magid, R. Brindis, L. W. Klein, W. B. Gibler, E. M. Ohman, et al.
Temporal Changes in the Use of Drug-Eluting Stents for Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention From 2006 to 2008: Results From the Can Rapid risk stratification of Unstable angina patients Supress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) and Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (ACTION-GWTG) Registries
Circ Cardiovasc Qual Outcomes,
September 1, 2009;
2(5):
414 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Khattab, C. W. Hamm, J. Senges, R. Toelg, V. Geist, T. Bonzel, M. Kelm, B. Levenson, C. A. Nienaber, T. Pfannebecker, et al.
Sirolimus-Eluting Stent Treatment at High-Volume Centers Confers Lower Mortality at 6-Month Follow-Up: Results From the Prospective Multicenter German Cypher Registry
Circulation,
August 18, 2009;
120(7):
600 - 606.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wijns
Late Stent Thrombosis After Drug-Eluting Stent: Seeing Is Understanding
Circulation,
August 4, 2009;
120(5):
364 - 365.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cook and P. Wenaweser
Off-Label Use and the Spectre of Drug-Eluting Stent Thrombosis
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
273 - 276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lasala, D. A. Cox, D. Dobies, K. Baran, W. B. Bachinsky, E. W. Rogers, J. A. Breall, D. H. Lewis, A. Song, R. M. Starzyk, et al.
Drug-Eluting Stent Thrombosis in Routine Clinical Practice: Two-Year Outcomes and Predictors From the TAXUS ARRIVE Registries
Circ Cardiovasc Interv,
August 1, 2009;
2(4):
285 - 293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2080 - 2097.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Ormiston and P. W.S. Serruys
Bioabsorbable Coronary Stents
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
255 - 260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
504 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Brar, M. B. Leon, G. W. Stone, R. Mehran, J. W. Moses, S. K. Brar, and G. Dangas
Use of Drug-Eluting Stents in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol.,
May 5, 2009;
53(18):
1677 - 1689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sibbing, J. Stegherr, W. Latz, W. Koch, J. Mehilli, K. Dorrler, T. Morath, A. Schomig, A. Kastrati, and N. von Beckerath
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
Eur. Heart J.,
April 2, 2009;
30(8):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
|
|
|
